In a significant development for the pneumococcal vaccine market, Vaxcyte has announced promising results from its Phase 1/2 trials, unveiling a vaccine that has the potential to challenge established leaders like Pfizer's Prevnar 20. The initial data not only showcases impressive efficacy but
Recursion Pharmaceuticals has reached a significant milestone in its journey to develop a treatment for cerebral cavernous malformation (CCM), a complex neurovascular condition. The company's leading experimental drug, REC-994, recently concluded a Phase 2 clinical trial, and the results are
In a strategic move to enhance its offerings in the biopharmaceutical sector, BioPhorum has announced the acquisition of Brookwood Global, a renowned UK-based training and educational content provider specializing in clinical research and drug safety. For over 15 years, BioPhorum has been a key
Bora Pharmaceuticals' recent strategic maneuvers have significantly bolstered its presence in the Contract Development and Manufacturing Organization (CDMO) sector, showcasing its intent to become a top contender in the biomanufacturing industry. In a notable move, Bora has acquired a 30.5%
The acquisition of a 30.5% stake in Tanvex Biopharma by Bora Pharmaceuticals is a pivotal development in the biotech sector. As the largest single corporate shareholder in Tanvex, Bora aims to leverage this strategic partnership to enhance its competitive edge in the global biopharmaceutical
The European Commission's recent authorization of Regeneron's bispecific antibody drug Ordspono (odronextamab) for the treatment of two types of lymphoma marks a significant milestone in the European market. Garnering approval for use across 27 European Union countries, Ordspono is now
The early-stage biotech investment landscape has undergone substantial changes in recent years. From the buoyant investment period during the pandemic to the current stabilization at pre-pandemic levels, the sector faces a mix of challenges and evolving strategies. One of the most significant
The Korea Biopharma Excellence Awards (KBEA) 2024 marked a significant moment for Avantor, a leader in providing mission-critical products and services across life sciences and advanced technologies. Avantor’s recognition at these awards underscores their unwavering commitment to innovation and e
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is such an innovative medicine, that it seems like something straight out of a science fiction novel. This gene editing technology allows scientists to precisely target spots in our DNA to fix mutations or stop disease-ridden parts
Sutro Biopharma has announced a significant step forward in the fight against lung cancer by initiating a global Phase 2 clinical trial, aptly named REFRαME-L1, for their innovative drug luveltamab tazevibulin (luvelta). This trial aims to evaluate the safety and efficacy of luvelta in adults with
